For the first time, Prime Therapeutics hosted the AMCP Nexus specialty keynote, addressing trends in cell and gene therapy and rare disease and immunology categories

Whitepaper Tab 1 Myth 1 Myth 2 Myth 3 Myth 4 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed nec ornare mi. Praesent ultrices ipsum eget est rutrum, eget congue orci molestie. Sed diam...

Clinical deep dive Disease state overview MacTel type 2 is a rare neurodegenerative disease that affects the macula, which processes central and color vision. It is a bilateral asymmetric...

Empowering client, providers and members Building a trusted, transparent PBM Tab 1 2021 – Current 2015 – 2020 2010 – 2014 1998 – 2009 Helping improve care, reducing cost through integration See our...

Publications High Cost Therapy Profile: October 2024 Eladocagene Exuparvovec October 15, 2024 References PTC Therapeutics announces FDA acceptance and Priority Review of the BLA for UpstazaTM. PTC...

Prime is pleased to present the seventh edition of the Employer Market Insights Report. Within this one-of-a-kind publication, you’ll find critical pharmacy trend insights that will help you make...

Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs

Marquee event showcased new Prime, our energy, ambition and transformative journey